+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Dilated Cardiomyopathy Therapeutic Market - Growth, Trends, and Forecasts (2020 - 2025)

  • ID: 4896105
  • Report
  • June 2020
  • Region: Global
  • 112 pages
  • Mordor Intelligence

FEATURED COMPANIES

  • AstraZeneca plc.
  • Pfizer Inc.
  • t2cure GmbH
  • Vericel Corporation
  • MORE
The dilated cardiomyopathy therapeutics market is anticipated to grow with a CAGR of nearly 3.6% during the forecast period. The major factors attributing to the growth of the dilated cardiomyopathy therapeutics market are increasing life expectancy and increasing prevalence of heart problems. Furthermore, the increasing number of people suffering from cardiac muscle infections, along with the drug or alcohol abuse are also the major factors that help in driving the growth of the market.

As the incidence of cardiovascular diseases is increasing which is directly proportional to the market growth. Whereas the side effects of dilated cardiomyopathy therapeutics that cause serious discomfort to the patients are restraining the market.

Key Market Trends

Angiotensin II receptor blockers is Expected to Dominate the Growth of the Market

Angiotensin II receptor blockers acquire the largest market share followed by beta-blockers. This is attributed to the high demand for blockbuster drugs in dilated cardiomyopathy treatment, especially in developed regions. Aldosterone antagonists recorded a high growth rate due to the identified positive impact of aldosterone antagonists when used in combination with either ARBs or ACE inhibitors in reducing the progression of Duchenne muscular dystrophy (DMD). Approval for this indication would further accelerate the overall sales of aldosterone antagonists, which in turn would positively impact market growth.

The other driving factors of the segment are also related to the increasing prevalence of heart diseases. Therefore as the prevalence of heart diseases increases the growth of the market increases too.

North America Dominates the Market and Expected to do Same in the Forecast Period

North America is expected to dominate the overall dilated cardiomyopathy therapeutics market, throughout the forecast period. The growth is due to the rising incidence of cardiovascular diseases, well-established insurance policies and the availability of advanced healthcare infrastructure are the major factors.

In the North America region, the United States holds the largest market share due to factors such as an increasing number of geriatric populations, along with a growing number of heart diseases in the country, which is anticipated to stimulate the demand in this region. Therefore as the number of cardiovascular diseases increases the market for dilated cardiomyopathy also increases.

Competitive Landscape

The dilated cardiomyopathy therapeutics market is moderately competitive and consists of several major players. Some of the companies which are currently dominating the market are Zensun Shanghai Sci & Tech Co Ltd, Capricor Therapeutics, Inc, AstraZeneca plc., Vericel Corporation, Pfizer inc., t2cure GmbH, MyoKardia, and Kasiak Research pvt.ltd.

Reasons to Purchase this report:
  • The market estimate (ME) sheet in Excel format
  • 3 months of analyst support

This report will be delivered within 2 business days.
Note: Product cover images may vary from those shown

FEATURED COMPANIES

  • AstraZeneca plc.
  • Pfizer Inc.
  • t2cure GmbH
  • Vericel Corporation
  • MORE
1 INTRODUCTION
1.1 Study Deliverables
1.2 Study Assumptions
1.3 Scope of the Study

2 RESEARCH METHODOLOGY

3 EXECUTIVE SUMMARY

4 MARKET DYNAMICS
4.1 Market Overview
4.2 Market Drivers
4.2.1 Increasing Prevalence of Heart Diseases
4.2.2 Increasing Drugs and Alcohol Abuse
4.3 Market Restraints
4.3.1 Side Effects of Dilated Cardiomyopathy Therapeutics
4.4 Porter's Five Force Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry

5 MARKET SEGMENTATION
5.1 By Drug Class
5.1.1 Aldosterone antagonists
5.1.2 Angiotensin-converting enzyme (ACE) Inhibitors
5.1.3 Angiotensin II Receptor Blockers
5.1.4 Beta-blockers
5.2 Geography
5.2.1 North America
5.2.1.1 United States
5.2.1.2 Canada
5.2.1.3 Mexico
5.2.2 Europe
5.2.2.1 Germany
5.2.2.2 United Kingdom
5.2.2.3 France
5.2.2.4 Italy
5.2.2.5 Spain
5.2.2.6 Rest of Europe
5.2.3 Asia-Pacific
5.2.3.1 China
5.2.3.2 Japan
5.2.3.3 India
5.2.3.4 Australia
5.2.3.5 South Korea
5.2.3.6 Rest of Asia-Pacific
5.2.4 Middle-East and Africa
5.2.4.1 GCC
5.2.4.2 South Africa
5.2.4.3 Rest of Middle-East and Africa
5.2.5 South America
5.2.5.1 Brazil
5.2.5.2 Argentina
5.2.5.3 Rest of South America

6 COMPETITIVE LANDSCAPE
6.1 Company Profiles
6.1.1 Zensun Shanghai Sci & Tech Co Ltd
6.1.2 Capricor Therapeutics, Inc.
6.1.3 Vericel Corporation
6.1.4 AstraZeneca plc.
6.1.5 Pfizer Inc.
6.1.6 t2cure GmbH
6.1.7 MyoKardia and Kasiak Research pvt.ltd.

7 MARKET OPPORTUNITIES AND FUTURE TRENDS
Note: Product cover images may vary from those shown
  • Zensun Shanghai Sci & Tech Co Ltd
  • Capricor Therapeutics, Inc.
  • Vericel Corporation
  • AstraZeneca plc.
  • Pfizer Inc.
  • t2cure GmbH
  • MyoKardia and Kasiak Research pvt.ltd.
Note: Product cover images may vary from those shown

Loading
LOADING...

Adroll
adroll